Re: Cell Study Finds Receptor Can Fight Tamoxifen-resistant Breast Cancer Cells
I think this could turn out to have important significance for us. The researcher states:
'Why would FXR work better against MCF-7TR, the tamoxifen-resistant cells? Part of the explanation may be that MCF-7TR relies more on HER2, and FXR targets HER2, Giordano said. That would make the tamoxifen-resistant cancer cells more vulnerable to activated FXR.'
Perhaps Her2+ will have even more impact from this finding if further studies continue to show the effect, particularly for triple positive BC cancer.
(Disclosure: I always pay attention when Professor Giordano is speaking. She is one of the few researchers advocating for male breast cancer patients these days.)
__________________
Male Breast Cancer, DX 5/15/09, IDC, STAGE 1, 1.7 cm, HER2+++, ER+(95%)/PR+(75%), Ki67 40%, grade 3, 0/5 nodes, TX: mastectomy, TCH finished 7/19/10, radiation 6 wks., Tamoxifen on going, bisphosphonate 24 mos.
|
Linear Mode
